XML 232 R12.htm IDEA: XBRL DOCUMENT
v3.20.1

Segment Reporting | 12 Months Ended
--- | ---
Dec. 31, 2019
Segment Reporting |
Segment Reporting | (6) Segment Reporting In accordance with IFRS 8 “Operating Segments”, financial information for operating segments is reported in the accompanying Appendix II, which forms an integral part of this note to the consolidated financial statements. Group companies are divided into four areas: companies from the industrial area, companies from the commercial area, companies from the services area and companies from the research area. Within each of these areas, activities are organized based on the nature of the products and services manufactured and marketed. Assets, liabilities, income and expenses for segments include directly and reliably attributable items. Items which are not attributed to segments by the Group are: Balance sheet: equity, cash and cash equivalents and loans and borrowings. Statement of profit and loss: finance result and income tax. (a)Operating segments The operating segments defined by the steering committee are as follows: Bioscience: including all activities related with products derived from human plasma for therapeutic use. Hospital: comprising all non-biological pharmaceutical products and medical supplies manufactured by Group companies earmarked for hospital pharmacy. Products related with this business which the Group does not manufacture but markets as supplementary to its own products are also included. Diagnostic: including the marketing of diagnostic testing equipment, reagents and other equipment, manufactured by Group or other companies. Bio Supplies: groups together all transactions related to biological products for non-therapeutic use, Kedrion production agreements, and third-party plasma sales channeled through Haema and Biotest. Others: including the rendering of manufacturing services to third party companies. Details of net sales by groups of products for 2019, 2018 and 2017 are as follows:
|  | Thousands of Euros
|  | 31/12/2019 |  | 31/12/2018 |  | 31/12/2017
Bioscience |  |  |  |  |  |
Haemoderivatives |  | 3,993,462 |  | 3,516,704 |  | 3,429,785
Diagnostic |  |  |  |  |  |
Transfusional medicine |  | 680,766 |  | 650,180 |  | 679,692
Other diagnostic |  | 19,937 |  | 19,797 |  | 23,377
Hospital |  |  |  |  |  |
Fluid therapy and nutrition |  | 47,677 |  | 52,574 |  | 47,699
Hospital supplies |  | 67,489 |  | 58,014 |  | 52,466
Bio supplies |  | 266,540 |  | 167,004 |  | 66,791
Others |  | 22,820 |  | 22,451 |  | 18,263
Total |  | 5,098,691 |  | 4,486,724 |  | 4,318,073
The Group has concluded that hemoderivative products are sufficiently alike to be considered as a whole for the following reasons: All these products are human plasma derivatives and are manufactured in a similar way. The customers and methods used to distribute these products are similar. All these products are subject to the same regulations regarding production and the same regulatory environment. (b)Geographical information Geographical information is grouped into four areas: United States of America and Canada Spain Rest of the European Union Rest of the world The definition of these four segments is mainly due to the geographical level that Group management sets to manage its revenue as they respond to specific economic scenarios. The main framework of the Group is consistent with this geographical segment grouping, including the monitoring of its commercial operations and its information systems. The financial information reported for geographical areas is based on sales to third parties in these markets as well as the location of assets. (c)Main customers In 2019, there are no customers representing more than 10% of the Group’s gross revenue. In 2018 the revenue of one Bioscience segment customer represented approximately 10.06% of the Group’s gross revenues. For 2017 one Bioscience segment customer represented 11.0% of the Group’s total gross revenue.

X
- Definition The entire disclosure for operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Section Disclosure -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration